Mahlknecht U - Search Results

1

Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.

Bellos F, Mahlknecht U. Bellos F, et al. Among authors: mahlknecht u. Onkologie. 2008 Nov;31(11):629-33. doi: 10.1159/000160599. Epub 2008 Oct 23. Onkologie. 2008. PMID: 19145098 Review.

2

Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins.

Bokelmann I, Mahlknecht U. Bokelmann I, et al. Among authors: mahlknecht u. Mol Med. 2008 Jan-Feb;14(1-2):20-7. doi: 10.2119/2007-00084.Bokelmann. Mol Med. 2008. PMID: 17973028 Free PMC article.

3

Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group.

Heilig CE, Löffler H, Mahlknecht U, Janssen JW, Ho AD, Jauch A, Krämer A. Heilig CE, et al. Among authors: mahlknecht u. J Cell Mol Med. 2010 Apr;14(4):895-902. doi: 10.1111/j.1582-4934.2009.00905.x. Epub 2009 Sep 14. J Cell Mol Med. 2010. PMID: 19754665 Free PMC article.

4

Successful treatment of disseminated central nervous aspergillosis in a patient with acute myeloblastic leukemia.

Mahlknecht U, von Lintig F, Mertelsmann R, Lindemann A, Lübbert M. Mahlknecht U, et al. Leuk Lymphoma. 1997 Sep;27(1-2):191-4. doi: 10.3109/10428199709068287. Leuk Lymphoma. 1997. PMID: 9373212

5

The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities.

Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Zhu JY, et al. Among authors: mahlknecht u. Int J Cancer. 2007 Oct 15;121(8):1839-46. doi: 10.1002/ijc.22883. Int J Cancer. 2007. PMID: 17565740 Free article.

6

Role of histone deacetylase inhibitors in the treatment of cancer (Review).

Mei S, Ho AD, Mahlknecht U. Mei S, et al. Among authors: mahlknecht u. Int J Oncol. 2004 Dec;25(6):1509-19. Int J Oncol. 2004. PMID: 15547685 Review.

7

The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.

Xu Y, Voelter-Mahlknecht S, Mahlknecht U. Xu Y, et al. Among authors: mahlknecht u. Int J Mol Med. 2005 Jan;15(1):169-72. Int J Mol Med. 2005. PMID: 15583844

8

Azacytidine causes complex DNA methylation responses in myeloid leukemia.

Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Stresemann C, et al. Among authors: mahlknecht u. Mol Cancer Ther. 2008 Sep;7(9):2998-3005. doi: 10.1158/1535-7163.MCT-08-0411. Mol Cancer Ther. 2008. PMID: 18790780 Clinical Trial.

9

Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G; Study Alliance Leukemia. Wandt H, et al. Among authors: mahlknecht u. Lancet. 2012 Oct 13;380(9850):1309-16. doi: 10.1016/S0140-6736(12)60689-8. Epub 2012 Aug 8. Lancet. 2012. PMID: 22877506 Clinical Trial.

10

Kunadt D, Dransfeld C, Dill C, Schmiedgen M, Kramer M, Altmann H, Röllig C, Bornhäuser M, Mahlknecht U, Schaich M, Stölzel F. Kunadt D, et al. Among authors: mahlknecht u. Ann Hematol. 2020 Sep;99(9):2173-2180. doi: 10.1007/s00277-020-04163-7. Epub 2020 Jul 3. Ann Hematol. 2020. PMID: 32621177 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page